Overexpression of GYS1, MIF, and MYC is associated with adverse outcome and poor response to azacitidine in myelodysplastic syndromes and acute myeloid leukemia

Jose F Falantes; Pablo Trujillo; Jose I Piruat; Cristina Calderón; Francisco J Márquez-Malaver; Beatriz Martín-Antonio; Africa Millán; Marina Gómez; Jose González; Maria L Martino; Isabel Montero; Rocío Parody; Ildefonso Espigado; Alvaro Urbano-Ispizua; Jose A Pérez-Simón

doi:10.1016/j.clml.2014.10.003

Overexpression of GYS1, MIF, and MYC is associated with adverse outcome and poor response to azacitidine in myelodysplastic syndromes and acute myeloid leukemia

Clin Lymphoma Myeloma Leuk. 2015 Apr;15(4):236-44. doi: 10.1016/j.clml.2014.10.003. Epub 2014 Oct 23.

Authors

Affiliations

¹ Department of Haematology, University Hospital Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS)/CSIC/Universidad de Sevilla, Sevilla, Spain. Electronic address: [email protected].
² Instituto de Biomedicina de Sevilla (IBIS)/CSIC/Universidad de Sevilla, Sevilla, Spain.
³ Department of Haematology, University Hospital Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS)/CSIC/Universidad de Sevilla, Sevilla, Spain.
⁴ Hospital Clinic, IDIBAPS and Institute of Research Josep Carreras, Barcelona, Spain.

PMID: 25487600
DOI: 10.1016/j.clml.2014.10.003

Abstract

Background: The prognosis of myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML) is very heterogeneous.

Patients and methods: We analyzed the prognostic value of several genes in a cohort of 85 MDS and AML patients.

Results: Overexpression of glycogen synthase 1 and macrophage migration inhibitory factor genes had an adverse outcome in multivariate analysis (P = .003 and P < .001, respectively). Furthermore, the higher expression of myelocytomatosis oncogene was associated with a lower response to azacitidine (P = .03).

Conclusion: In the current study we identified a specific gene expression profile as prognostic factors for response to azacitidine and survival in MDS and AML.

Keywords: Acute leukemia; Azacitidine; Gene expression; Myelodysplastic syndromes; Prognosis.

MeSH terms

Aged
Aged, 80 and over
Antimetabolites, Antineoplastic / therapeutic use
Azacitidine / therapeutic use
Gene Expression Profiling
Gene Expression*
Genes, myc*
Glycogen Synthase / genetics*
Humans
Hypoxia / genetics
Intramolecular Oxidoreductases / genetics*
Leukemia, Myeloid, Acute / diagnosis
Leukemia, Myeloid, Acute / drug therapy*
Leukemia, Myeloid, Acute / genetics*
Leukemia, Myeloid, Acute / mortality
Macrophage Migration-Inhibitory Factors / genetics*
Middle Aged
Myelodysplastic Syndromes / diagnosis
Myelodysplastic Syndromes / drug therapy*
Myelodysplastic Syndromes / genetics*
Myelodysplastic Syndromes / mortality
Prognosis
Survival Analysis
Treatment Outcome

Substances

Antimetabolites, Antineoplastic
Macrophage Migration-Inhibitory Factors
Glycogen Synthase
Intramolecular Oxidoreductases
MIF protein, human
Azacitidine